Hyper-IL-6 gene therapy reverses fulminant hepatic failure.
Fulminant hepatic failure is a catastrophic condition caused by massive hepatocellular apoptosis and necrosis. Inhibition of hepatocyte apoptosis and the enhancement of the endogenous potential for liver regeneration could potentially form an effective basis for treatment of this condition. In response to injury in the liver, IL-6 mediates the acute-phase response and induces both cytoprotective and mitogenic functions. Hyper-IL-6 is a superagonistic designer cytokine consisting of human IL-6 linked by a flexible peptide chain to the secreted form of the IL-6 receptor. In a mouse model of acute liver failure induced by d-galactosamine administration, a single low dose of a hyper-IL-6-encoding adenoviral vector, in contrast to an adeno-IL-6 vector, maintained liver function, prevented the progression of liver necrosis, and induced liver regeneration, leading to dramatically enhanced survival. Thus, hyper-IL-6 gene therapy may be useful for the treatment of fulminant hepatic failure, which is often fatal even following treatment by transplantation.
Hecht
N
N
Liver Unit, The Goldyne Savad Institute for Gene Therapy, Ein Kerem, Jerusalem 91120, Israel.
Pappo
O
O
Shouval
D
D
Rose-John
S
S
Galun
E
E
Axelrod
J H
JH
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D017209:Apoptosis; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D015850:Interleukin-6 / Q000096:biosynthesis*; D008099:Liver / Q000473:pathology; D017093:Liver Failure / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008957:Models, Genetic; D009336:Necrosis; D010455:Peptides / Q000378:metabolism; D012038:Regeneration; D013997:Time Factors
D015850:Interleukin-6; D010455:Peptides